Microsoft word - vitae_dr clark.doc

Board-Certified Dermatologist Lubbock Dermatology and Skin Cancer Center ADDRESS:
Dermatology Residency - July 1997 – June 2000 UNIVERSITY OF TEXAS MEDICAL BRANCH, Galveston, Texas Pediatric Internship - June 1996 - June 1997 GRADUATE EDUCATION:
UNIVERSITY OF TEXAS MEDICAL BRANCH, Galveston, Texas Doctor of Medicine with Honors, August 1992 - May 1996 UNDERGRADUATE
Bachelor of Science, August 1987 - May 1991 - magna cum laude PROFESSIONAL
Texas State Board of Medical Examiners - 1998 LICENSURE:

American Board of Dermatology, October 2000 PROFESSIONAL
American Academy of Dermatology, Fellow, 2000 - present ORGANIZATIONS:
Texas Dermatological Society, Member 2001 - present American Medical Association, 1994 - present Texas Medical Association, 1992 - present Lubbock-Crosby-Garza Medical Society, 1997 -present American Society for Lasers in Surgery and Medicine, 2002-present Alpha Omega Alpha, University of Texas Medical Branch, 1995 Gold-Headed Cane Award nominee, University of Texas Medical Branch, 1996 Alpha Chi Honor Scholarship Society, Angelo State University, 1990 Who's Who Among Students in American Universities and Colleges, Angelo COMMUNITY SERVICE:
American Academy of Dermatology annual skin-cancer screenings, 1998 – present Lubbock Community Health Center annual skin-cancer screening, 2001-present Lubbock City Health Department skin-cancer screening, 1999 Lubbock Cooper High School skin-cancer screening, 1999 RESEARCH:

Rapini RP, Clark JW: A double-blind, randomized, placebo controlled,
multicenter, parallel group evaluation of the efficacy and safety of sertaconazole 2% cream on patients with interdigital tinea pedis. Butler DF, Clark, JW: A 26-week study with a 6-week randomized multicenter, double-blind, vehicle-controlled,
parallel-group phase followed by a 20-week, open-label phase to study the safety and efficacy of 1% SDZ ASM 981 cream in pediatric subjects with atopic dermatitis. Phase IV Open-label, observational cohort study – Assessment and Tracking of long-term Phase IV 12 week open-label, observation study to evaluate adapalene gel 0.1% as part of a Combination therapy regimen in moderate to moderately severe acne 2006 Phase IV Open-label 4 week trial to evaluate patient satisfaction with clobetasol proprionate 0.05% when used as monotherapy or as add-on therapy for the treatment of Phase III Multi-Center, randomized, double-blind, parallel-group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. Phase IV Observational Post-Marketing Safety Surveillance Registry of etanercept for the treatment Phase III randomized, double-blind, multiple-site, placebo controlled, parallel design, clinical study to evaluate the bioequivalence of generic Adapalene Gel 0.1% compared to brand adapalene 0.1% 1. Clark JW, 9/6/98, Santa Fe, New Mexico, "Generalized Lichen Planus", Southwestern Dermatological Society 2. Clark JW, Butler DF, Rapini RP, 5/8/99, Dallas, Texas, "Uncommon Presentations of Langerhans Cell Histiocytosis", Texas Dermatological Society Spring Meeting 3. Clark JW, Butler DF, Bang R, 3/10/00, San Francisco, California, "Fatal Sporotrichosis", Gross and Microscopic Symposium, 58th Annual Meeting of the American Academy of Dermatology 4. Clark, JW, 3/6/02, Lubbock, Texas, “Warts and Acne”, Pediatric Grand Rounds, Covenant Medical Center 5. Clark, JW, 5/31/02, Lubbock, Texas, “Atopic Dermatitis”, Pediatric Symposium, Covenant Medical Center


Microsoft word - st9_en.doc

M. A. Sulamanidze, MD, P. F. Fournier, MD, T. G. Paikidze, MD, and G. M. Sulamanidze, MD. Removal of Facial Soft Tissue Ptosis With Special Threads // Dermatologic Surgery. May 2002. Number 5. Volume 28. P. 367-371. Removal of Facial Soft Tissue Ptosis With Special Threads M. A. Sulamanidze, MD, P. F. Fournier, MD, T. G. Paikidze, MD, and G. M. Sulamanidze, MD Clinic of Plastic and Aest

Material Safety Data Sheet HAZARDOUS Catalog Number: 103011 Revision date: 10-Mar-2005 Australia Hazardous Statement: Hazardous according to criteria of NOHSC 1. COMPANY DETAILS Supplier: MP Biomedicals Australasia Pty Limited Unit 12, 167 Prospect Hwy. Seven Hills, NSW 2147 Aust. Telephone Number: Fax Number: Emergency telephone number: (02) 9838 7422: hours: 8.30 A

Copyright © 2010-2014 Online pdf catalog